AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
GRI Bio: Ascendiant Capital maintains a 'Buy' Rating, The Target Price is $36
ByAinvest
Monday, Dec 8, 2025 7:00 am ET1min read
Ascendiant Capital maintains 'Buy' rating on GRI Bio(GRI).
The target price is $36, compare with $35 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-12-08 | Ascendiant Capital | Maintains | Buy | Buy | $36 | $35 |
[Recent Earning Results] Gri Bio posted the Q3 of its 2025 financial results on 11/14/2025, reporting net income of USD -9.30 million in the first three quarters, expanding 48.54% from USD -6.26 million year over year.
[Company Profile] GRI Bio, Inc. was incorporated under the laws of the State of Delaware on January 11, 2018. The company is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The company goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet